ID-5184 Wonca Abstracts supplement A-K 13-10-23 - Flipbook - Page 202
WONCA 2023 Supplement 1: WONCA 2023 abstracts (A–K)
A
B
C
D
The success of gender-affirming hormone therapy with
testosterone in general practice: The PUSH! Audit
Dr Beng Eu1, Joshua Dawe2, Matthew Dunn3, Julian Grace4, Kevin Lee5, Scott Griffiths6, Mark Bloch7,8,
David Baker9, Clara Soo10, Fiona Bisshop11, Mark Stoové2,5,11
1
E
F
G
H
I
J
K
Prahran Market Clinic, 2Burnet Institute, 3Deakin University, 4Trans Health Research, The University of
Melbourne, 5Monash University, 6The University of Melbourne, 7University of NSW, 8Holdsworth House,
9
East Sydney Doctors, 10Hobart Place Medical, 11La Trobe University
Introduction
Gender-affirming hormone therapy (GAHT) is often managed in general practice in Australia. The
increasing use of the informed consent model of care is likely to increase this practice in the future.
Many GPs are not familiar with this practice and have concerns about the potential adverse effects that
the hormone treatment may cause. By collecting data from GP clinics, this study aims to describe this
population and highlight any significant issues that might arise from this treatment in general practice.
Aim
The PUSH! Audit was a cross-sectional study collecting data from nine GP clinics across Australia that
provide GAHT. This study describes the demographics of the patient population who are prescribed
testosterone as GAHT. The study also collected data about serum testosterone levels, measured
adverse effects and self-reported adverse effects experienced by this patient population.
Results
This study shows the wide demographics of these patients, with many younger individuals seeking this
treatment. It also collected information about diagnoses of anxiety and depression in this population.
They achieved good testosterone levels on treatment and experienced minimal adverse effects –
either measured or self-reported. The measured adverse effects included haemoglobin levels (for
polycythaemia), blood pressure readings (for hypertension), lipid levels (for hyperlipidaemia), liver
function test results and renal function test results. The self-reported adverse effects included balding,
acne, depression, aggression and mania.
Conclusion
GAHT with testosterone can be managed effectively in general practice with good results achieved.
There are high rates of success and very few adverse effects associated with this treatment. This
study also confirms the high incidence of mental health diagnoses (anxiety and depression in this
study) in this population, which is consistent with many previous studies. This study should give
confidence to GPs in providing this treatment as part of general practice.
200